Cell Cycle/Checkpoint Antibody Sampler Kit					
Store			C	orders:	877-616-CELL (2355) orders@cellsignal.com
1 Kit (6 x 20 microliters)			S	upport:	877-678-TECH (8324)
			Web:		info@cellsignal.com cellsignal.com
For Research Use Only. Not for	Use in Diagnostic Procedures.		3 Trask Lane	Danvers Ma	ssachusetts 01923 USA
Product Includes		Product #	Quantity	Mol. Wt	Isotype/Source
Phospho-cdc2 (Tyr15) (10A11) Rabbit mAb		4539	20 µl	34 kDa	Rabbit
Phospho-Chk1 (Ser345) (133D3) Rabbit mAb		2348	20 µl	56 kDa	Rabbit IgG
Phospho-Chk2 (Thr68) (C13C1) Rabbit mAb		2197	20 µl	62 kDa	Rabbit IgG
Phospho-Rb (Ser807/811) (D20B12) XP [®] Rabbit mAb		8516	20 µl	110 kDa	Rabbit IgG
Phospho-Rb (Ser795) Antibody		9301	20 µl	110 kDa	Rabbit
Phospho-p53 (Ser15) (16G8) Mouse mAb		9286	20 µl	53 kDa	Mouse IgG1
Anti-rabbit IgG, HRP-linked Antibody		7074	100 µl		Goat
Anti-mouse IgG, HRP-linked Antibody		7076	100 µl		Horse
Storage Background	secondary antibody to perform four Supplied in 10 mM sodium HEPES 0.02% sodium azide. Store at -20 The cell division cycle demands ac controlled by molecular circuits cal Checkpoints monitor DNA integrity transitions, respectively. The cdc2- phosphorylated at Thr14 and Tyr19 The tumor suppressor protein retir point (R) and is a major regulator of and represses the transcription fac induces Rb to dissociate from E2F can be phosphorylated at multiple G2/M and the G1/S checkpoints. In phosphorylate Chk at Ser345 (9), phosphorylation at Ser216, blocking	r Western blot exper S (pH 7.5), 150 mM N °C. Do not aliquot the ccuracy to avoid the lled "checkpoints" tha v and cell growth prio ccyclin B kinase is pir 5 during G2-phase b noblastoma (Rb) con of the G1/S transition ctor E2F (5). The pho c, permitting the trans sites by cdc2, cdk2, DNA damage activate Chg2 at Thr68 (10) a mg the activation of co	riments. NaCl, 100 µg/ml e antibody. accumulation or at are common or to replication a votal in regulatin vy the kinases W trols progressio n (4). During ear osphorylation of scription of S-ph and cdk4/6 (6-8 es the DNA-PK/ and p53 (11). Th dc2.	BSA, 50% gly f genetic dama to all eukaryot and division at ng the G2/M tr /ee1 and Myt1 n through the rly and mid G1 Rb late in G1. ase-promoting 3). DNA dama ATM/ATR kina e Chk kinases	ycerol and less than age. This process is tic cells (1). t the G1/S and G2/M ansition (2,3). Cdc2 is L, rendering it inactive. late G1 restriction -phase, Rb binds to -phase by CDKs g genes. <i>In vitro</i> , Rb ge triggers both the ases, which s inactivate cdc25 via
Background References	 Nurse, P. (1997) <i>Cell</i> 91, 865-7. Norbury, C. and Nurse, P. (1992) Watanabe, N. et al. (1995) <i>EMB</i> Sherr, C.J. (1996) <i>Science</i> 274, Dyson, N. (1998) <i>Genes Dev</i> 12 Kitagawa, M. et al. (1996) <i>EMB</i> Lundberg, A.S. and Weinberg, R Harbour, J.W. et al. (1999) <i>Cell</i> 9 Zhao, H. and Piwnica-Worms, H Matsuoka, S. et al. (2000) <i>Proc</i> 1 Tibbetts, R.S. et al. (1999) <i>Gene</i>) Annu Rev Biochem O J 14, 1878-91. 1672-7. , 2245-62. D J 15, 7060-9. A. (1998) Mol Cell B 08, 859-69. . (2001) Mol Cell Bio Natl Acad Sci USA 9 Is Dev 13, 152-7.	9 61, 441-70. Biol 18, 753-61. Dl 21, 4129-39. 7, 10389-94.		

Trademarks and	Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.		
Patents	U.S. Patent No. 7,429,487, foreign equivalents, and child patents deriving therefrom.		
	All other trademarks are the property of their respective owners. Visit cellsignal.com/trademarks for more		
	information.		

Cell Cycle/Checkpoint Antibody Sampler Kit (#9917) Datasheet Without Images Cell Signaling Technology

Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.